

() Page: 1/1

## **Committee on Technical Barriers to Trade**

Original: English

## **NOTIFICATION**

## Addendum

The following communication, dated , is being circulated at the request of the delegation of  $\underline{\mathsf{Brazil}}$ .

Title: Resolution - RDC number 620, 09 March 2022

Reason for Addendum:	
[]	Comment period changed - date:
[]	Notified measure adopted - date:
[]	Notified measure published - date:
[]	Notified measure enters into force - date:
[]	Text of final measure available from <sup>1</sup> :
[]	Notified measure withdrawn or revoked - date: Relevant symbol if measure re-notified:
[X]	Content or scope of notified measure changed and text available from¹:  https://antigo.anvisa.gov.br/documents/10181/3676755/RDC 858 2024 .pdf/3416e5 64-b181-4f93-9308-2580325bf310  New deadline for comments (if applicable):
[]	Interpretive guidance issued and text available from <sup>1</sup> :
[]	Other:

**Description:** Resolution 620, 09 March 2022 - previously notified through G/TBT/N/BRA/1324 - which contains provisions on the Certification of Good Practices for conducting Bioavailability/Bioequivalence studies of medicaments and defines which Bioavailability/Bioequivalence studies of medicines must be carried out in certified research centers, was changed by Resolution 858, 06 May 2024.

\_\_\_\_

<sup>&</sup>lt;sup>1</sup> This information can be provided by including a website address, a pdf attachment, or other information on where the text of the final/modified measure and/or interpretive guidance can be obtained.